Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease

INTRODUCTION: Solanezumab is a humanized monoclonal antibody that preferentially binds to soluble amyloid β and promotes its clearance from the brain in preclinical studies. The objective of this study was to assess the effect of solanezumab in slowing global and anatomically localized brain atrophy...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Alzheimers Dement (N Y)
Hlavní autoři: Schwarz, Adam J., Sundell, Karen L., Charil, Arnaud, Case, Michael G., Jaeger, Ralf K., Scott, David, Bracoud, Luc, Oh, Joonmi, Suhy, Joyce, Pontecorvo, Michael J., Dickerson, Bradford C., Siemers, Eric R.
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2019
Témata:
Featured Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6675941/
https://ncbi.nlm.nih.gov/pubmed/31388559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2019.05.007
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky